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Abstract
Currently used factors predicting disease recurrence in stage II colorectal cancer patients
are not optimal for risk stratification. Thus, new biomarkers are needed. In this study the
applicability of ezrin protein expression together with MSI status and BRAF mutation status
were tested in predicting disease outcome in stage II colorectal cancer. The study popula-
tion consisted of 173 stage II colorectal cancer patients. Paraffin-embedded cancer tissue
material from surgical specimens was used to construct tissue microarrays (TMAs) with
next-generation technique. The TMA-slides were subjected to following immunohistochemi-
cal stainings: MLH1, MSH2, MSH6, PMS2, ezrin and anti-BRAF V600E antibody. The stain-
ing results were correlated with clinicopathological variables and survival. In categorical
analysis, high ezrin protein expression correlated with poor disease-specific survival (p =
0.038). In univariate analysis patients having microsatellite instabile / low ezrin expression
tumors had a significantly longer disease-specific survival than patients having microsatel-
lite stable / high ezrin expression tumors (p = 0.007). In multivariate survival analysis, the
presence of BRAF mutation was associated to poor overall survival (p = 0.028, HR 3.29,
95% CI1.14–9.54). High ezrin protein expression in patients with microsatellite stable
tumors was linked to poor disease-specific survival (p = 0.01, HR 5.68, 95% CI 1.53–21.12).
Ezrin protein expression is a promising biomarker in estimating the outcome of stage II colo-
rectal cancer patients. When combined with microsatellite status its ability in predicting dis-
ease outcome is further improved.
Introduction
Five-year survival in stage II colorectal cancer (CRC) is 70–80% [1,2]. Unfavorable prognostic
factors for stage II CRC include lymphovascular invasion, less than 12 examined lymph nodes,
poor differentiation grade, tumor spreading to the peritoneum or adjacent tissue structures as
well as tumor obstruction or perforation. [3,4]. These risk factors have been utilized in the
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assessment of stage II colorectal cancer patients in need of postoperative adjuvant treatments.
The benefit of chemotherapy in stage III colorectal cancer patients is apparent, but controver-
sial in stage II colorectal cancer patients even with above-mentioned risk factors [5]. Conse-
quently, there is a crucial need to discover new markers to better define those at highest
danger of disease recurrence.
DNA mismatch repair competence is a feature associated with CRC outcome. Inactivation
of genes responsible for mismatch repair competence cause microsatellite instability (MSI),
which can be studied by expression of the gene products MLH1, MSH2, MSH6 and PMS2 or
by PCR-based methods [6,7,8,9,10,11]. MSI is reported in about 15–20% of CRC [8,12]. MSI is
linked to right-sided, poorly differentiated tumors with higher T stage and younger patient age
[12]. Stage II CRCs with MSI, as demonstrated by immunohistochemistry of mismatch repair
proteins, have a more favorable prognosis as compared to microsatellite stable (MSS) tumors
[13,14,4]. Moreover, patients with defective mismatch repair (dMMR) stage II tumors do not
seem to benefit from fluorouracil-based adjuvant chemotherapy [15,16]. MSI tumor can evolve
in Lynch syndrome patients carrying a germ-line mutation in one MMR gene, or through spo-
radic events involving epigenetic silencing of the MLH1 gene [17].
BRAF gene encodes a protein kinase of the RAS/RAF/MEK-ERK signaling cascade, which is
regulated by KRAS [18,19]. Previously, BRAF V600E mutation was shown to be an adverse
prognostic factor for overall survival in stage II-III colon cancer [20]. MSS together with BRAF
mutation is associated with poor prognosis in CRC [9,21]. On the contrary, MSI stage II
tumors with BRAFV600Emutation are associated with a rather favorable prognosis [21].
Moreover, colorectal cancer with MSI phenotype and a concomitant BRAF mutation indicates
a sporadic tumor, thus excluding Lynch syndrome [17,21].
Ezrin is a cytoskeleton-associated protein, which participates in cellular signaling, cell sur-
vival, proliferation and migration. Its association with malignant behavior has been suggested
in several experimental models, and in several cancers strong ezrin expression correlates with
inferior outcome. [22,23,24,25,26,27,28]. Our previous work has demonstrated the impact of
ezrin expression on the outcome in metastatic CRC as well as in localized rectal cancer [27,28].
To our knowledge, the role of ezrin as a prognostic marker in stage II colorectal cancer has not
been studied before.
In this work, we utilized tumor tissue collection form consecutive stage II CRC patients,
together with extensive clinical, disease outcome and follow-up data to search for tissue-based
prognostic markers. We report the association of MSI status, BRAFmutation status and ezrin
protein expression with clinicopathological variables and patient outcome. Our results suggest
that combined MSI and ezrin analysis can stratify tumors according to their clinical behavior.
Patients and methods
Study population
We collected archived paraffin-embedded tumor material from consecutive stage II CRC
patients operated in Turku University Hospital in 2005–2012. This study was approved by
Chief Executive Officer of TYKS-SAPA, Hospital District of Southwest Finland (T52/2014).
The use of tissue material was approved by Scientific Steering Group of Auria Biobank (AB15-
8108, 25.5.2012). The study was conducted in accordance with the Declaration of Helsinki.
The clinical data were retrieved and histological samples collected and analyzed with the
endorsement of the National Authority for Medico-Legal Affairs (VALVIRA). The patient rec-
ords were accessed anonymously.
In 2005–2012 a total of 232 stage II CRC patients were radically operated in our hospital.
Computed tomography (CT) of the abdomen and chest x-ray or CT had been performed
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preoperatively to rule out distant metastases. We carefully checked the patient files, including
surgery and pathology reports and excluded patients with verified lymph node or distant
metastases, those who had been operated with palliative-intent surgery, and also patients with
other than adenocarcinoma histology (e.g. neuroendocrine tumors). Only patients with stage
II CRC were included in the current study. For tumor staging, TNM7 classification of malig-
nant tumors [29] was used. From the original cohort (n = 232), tumor material for MSI stain-
ing was available from 214 patients. For further BRAF and ezrin stainings, material was
available from 173 patients. These patients (n = 173) were included in statistical analyses.
TMA construction
Tissue microarrays (TMA) were constructed and analyzed using the next-generation TMA
technique [30]. Shortly, the appropriate formalin-fixed paraffin-embedded (FFPE) tissue speci-
mens were chosen based on clinical data and retrieved from the pathology archives. A represen-
tative hematoxylin-eosin (H&E) section containing areas of invasive carcinoma was selected
from each tumor. New H&E slides were produced, scanned (Pannoramic P250, 3DHistech)
and uploaded into the university digital microscopy web portal (casecenter.utu.fi). Each slide
was viewed using Pannoramic Viewer software (3DHistech). Using the 1.2 mm diameter anno-
tation tool, annotations of different colors corresponding to various histological areas were
placed onto each digital slide. Two annotations were placed in the center of the tumor, two in
the tumor front and two in the normal colonic epithelium. The corresponding tissue cores were
then transferred into the TMA blocks using an automated TMA instrument (TMA Grandmas-
ter, 3DHistech) by overlaying each annotated digital slide with the corresponding tissue speci-
men. One tissue core containing benign tissue was selected from each tumor to act as a control.
The constructed TMA blocks were sectioned, stained, scanned and uploaded into the web por-
tal (casecenter.utu.fi) and each individual spot was scored by two pathologists (KS, JS). The
resulting scores were combined with the clinical data for statistical analysis.
Immunohistochemistry
Immunohistochemical staining against MMR proteins is a useful screening method in
research materials with paraffin-embedded TMA-samples. In contrast to PCR-based methods,
it also readily provides information on the inactivated gene. Immunohistochemical stainings
(IHC) were performed using standard procedures. Shortly, 3,5 μm sections were cut from the
TMA blocks. They were stained with monoclonal antibodies against MLH1 (Clone G168-
15BD Pharmingen, dilution: 1:5), MSH2 (Clone G219-1129, BD Pharmingen, dilution: 1:200)
and MSH6 (Clone EP49, Epitomoc, dilution: 1:200). The signal was detected with UltraView
Universal DAB Detection kit. For PMS2, Clone EPR3947 (Ventana/Roche, ready to use anti-
body) was used and the signal was detected with OptiView Universal DAB Detection Kit and
amplification kit. To detect BRAFV600E mutation, BRAF RTU antibody (Clone VE1, Roche/
Ventana) was used and the signal was detected with OptiView Universal DAB Detection kit.
For ezrin staining, immunoglobulin G antibody to human ezrin (clone 3C12) [31] was used.
All the stainings were performed with BenchMark XT (Ventana/Roche) using ultraVIEW Uni-
versal DAB Detection Kit (Ventana/Roche), except ezrin, which was done with LabVision
immunoautomate (Thermo Fisher Scientific) using the Power Vision Plus poly HRP anti-
mouse/rabbit/rat IgG detection kit.
Evaluation of immunohistochemical stainings
All IHC stainings were separately evaluated by two observers (KS and JS), blinded to clinical
data. For MLH1, MSH2, MSH6, PMS2 and ezrin, inflammatory cells of the stroma were used
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as positive controls. For analyses of MSI (MLH1, MSH2, MSH6 and PMS2) also the cores
from normal colonic epithelium were used as positive controls. As a positive control in evalu-
ating the BRAF-stainings, we used BRAFV600Emutation-positive cancer tissue obtained
from a CRC patient who did not belong to this study cohort. These IHC stainings were evalu-
ated dichotomously as positive or negative. For ezrin protein expression, cytoplasmic staining
was recorded [27, 28].Four staining categories were used: 0 for negative staining, 1 for weak
staining (distinguishable from the background staining), 2 for moderate staining and 3 for
strong staining (corresponding to immunoreactivity in lymphocytes) [27]. In addition, a cate-
gory of non-evaluable was used for all stainings. For statistical purposes a dichotomous grad-
ing, ezrin low (negative or weak staining) and ezrin high (moderate or strong staining) was
used.
Statistical analysis
Statistical analyses were performed with IBM SPSS version 23 with standard packages. Clinical
data were analyzed in correlation with histological, immunohistochemical and mutational
analysis data using χ2 or Fisher’s exact-test for discrete variables and one-way ANOVA for
continuous variables. Overall survival (OS), disease free survival (DFS) and disease-specific
survival (DSS) were calculated using Kaplan-Meier curves. Survival was analyzed with respect
to (stratified to) different biomarkers using log-rank test. For multivariate analyses, the follow-
ing variables were used: tumor grade, tumor-side, obstruction, perforation, vascular invasion,
BRAFmutated/wild type, ezrin low/high and MSS/MSI combinations were included. Multivar-
iate Cox proportional hazard regression model was used to adjust the survival curves for covar-
iates and to obtain estimates on hazard ratios. All p-values were two-sided, and values less
than 0.05 were considered statistically significant.
Results
General aspects of clinical patient characteristics
Altogether 173 patients were included in this study. The tumor was located in the proximal
colon in 70 (40%), transverse colon in 19 (11%), descending colon in 8 (5%), sigmoid colon in
44 (25%) and rectum/rectosigmoideum in 32 (19%) patients. There were 30 (17%) T4-tumors
included in the study. Vascular invasion was reported in 32 (18%) patients and preoperative
bowel obstruction in 26 (15%) of patients. Adjuvant fluorouracil-based chemotherapy had
been given to 51 (30%) patients. The median follow-up time was 57 months. At the latest fol-
low-up data collection time point in September 2016, 116 patients (67%) were alive without
CRC, 3 (2%) alive with CRC, 17 dead of CRC, 18 (10%) dead of other cancers and 19 (11%)
dead of other causes than cancer. The clinical characteristics of the patients are shown in
Table 1.
General aspects of MSI staining
The results of the MSS/MSI analysis in relation to clinicopathological variables are shown in
Table 2. Overall, 136 (79%) of the tumors were MSS and 37 (21%) were MSI high. MSI was sig-
nificantly more common in the right-sided tumors (n = 30; 34%), as compared with the left-
sided tumors (n = 7; 8%) (Pearson’s chi-square test, p = 0.0001). MSI was infrequent in well-
differentiated tumors (1/39, 3%), but common in tumors with poor differentiation grade (15/
39, 40%). Ten out of 22 (45%) mucinous cancers presented MSI. MSI status in relation to
clinic-pathological variables is presented in Table 2.
Ezrin expression with MSI in stage II colorectal cancer
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General aspects of ezrin staining
The results of the ezrin stainings in relation to clinicopathological parameters are shown in
Table 3. Generally, in 135 (78%) tumors, ezrin staining intensity was scored as low, and in 38
Table 1. The clinicopathological variables of the patient population included in the MSI, BRAF and
Ezrin analyses (n = 173). NA = not available, R0 = microscopically radical surgery, R1 macroscopically radi-
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Table 2. MSS/MSI status in relation to clinicopathological variables (n = 173). NA = not available, R0 = microscopically radical surgery,
R1 = macroscopically radical surgery, R2 = macroscopically non-radical surgery, CRC = colorectal cancer.
Variable MSS MSI high Significance (p)
n (%) n (%)
Gender 0.266
Female 69 (51) 23 (62)
Male 67 (49) 14 (38)
Age 0.707
Under 70 years 53 (39) 13 (35)
Over 70 years 83 (61) 24 (65)
Postoperative stage 0.253
T3N0 115 (85) 28 (76)
T4aN0 13 (10) 4 (11)
T4bN0 8 (6) 5 (13)
Tumor side 0.0001
Right 59 (43) 30 (81)
Left 77 (57) 7 (19)
Tumor grade 0.010
G1 18 (13) 1 (3)
G2 93 (68) 21 (57)
G3 25 (18) 15 (40)
Histology 0.009
Conventional adenocarcinoma 124 (91) 27 (73)
Mucinous adenocarcinoma 12 (9) 10 (27)
Vascular invasion 0.383
Yes 28 (21) 4 (11)
No 101 (74) 30 (81)
NA 7 (5) 3 (8)
Lymph node count 0.646
12 or more examined 107 (78) 31 (84)
Less than 12 examined 29 (21) 6 (16)
Radicality of surgery 0.446
R0 128 (94) 34 (92)
R1 5 (4) 3 (8)
R2 3 (2) 0 (0)
Preoperative obstruction 0.604
Yes 22 (16) 4 (11)
No 114 (84) 33 (89)
Tumor perforation 0.797
Yes 11 (8) 4 (11)
No 124 (91) 33 (89)
NA* 1 (1) 0 (0)
Adjuvant chemotherapy 0.218
Yes 37 (27) 14 (38)
No 99 (73) 22 (59)
NA* 0 (0) 1 (3)
(Continued )
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(28%) as high. High ezrin expression was more common in MSI tumors (19/37, 51%) than in
MSS tumors (19/134, 14%) (Pearson’s chi-square test, p = 0.0001). There were no statistically
significant differences in ezrin intensity according to clinicopathological variables, except for
disease outcome (see below). Ezrin staining in relation to clinic-pathological variables is pre-
sented in Table 3.
BRAF staining
BRAF staining was available from 171 patients. Of the tumors, 146 (85%) were BRAFwild type
and 25 (15%) BRAFV600Emutated. The BRAFmutated tumors predominantly presented
with MSI (21/25, 84%), whereas BRAFwild type tumors were mostly MSS (130/146, 89%). Of
the BRAFwild type tumors only 25/146 (17%) showed high ezrin IHC, while 13/25 (52%) of
BRAFmutant tumors were ezrin high (Pearson’s chi-square test, p = 0.0001). Combinatorial
analysis of the three variables showed that BRAFwild type tumors were predominantly MSS /
low ezrin (112/146, 77%), whereas 12/25 (48%) of the BRAFmutated tumors were MSI / high
ezrin (Fisher’s exact test, p = 0.0001). Follow-up data according to BRAF status is presented in
Table 4.
Clinical correlations
The clinical correlations of the MSI status and ezrin staining are shown in Tables 2 and 3. Alto-
gether, high ezrin staining correlated with inverse DSS (Fisher’s exact test, p = 0.038). On the
other, MSI status as a single variable did not correlate with survival. In categorical analysis of
5-year disease-specific survival time, 11 out of 18 (61%) patients with MSI / low ezrin were
alive compared to only 4 out of 18 (21%) patients with MSS / high ezrin (Fisher’s exact test,
p = 0.040). In univariate analysis, patients whose tumors were MSI / low ezrin tended to have
the best OS probability, and those with MSI / high ezrin the worst, but the difference was not
statistically significant (log-rank test, p = 0.235). Patients with MSI / low ezrin tumors had the
longest DSS and those with MSS / high ezrin tumors had the shortest (log-rank test, p = 0.007).
An example of staining patterns of patients belonging to groups of best and worst DSS are pre-
sented in Figs 1 and 2, respectively. Patients with MSI / low ezrin had the longest DFS and
those with MSI / high ezrin had the shortest, but the difference was no statistically significant
(log-rank test, p = 0.069). The survival curves are presented in Fig 3 and the results of univari-
ate survival analysis in S1 Table.
A summary of the multivariate analyses results is presented in Table 5. This table shows
T4bN0 tumors to be associated with inferior OS (Cox model, HR 2.86, 95% CI [1.06–7.74],
p = 0.038) and DFS (Cox model, HR 8.05, 95% CI [2.31–28.01], p = 0.001). Likewise, perfora-
tion was linked to inferior OS (Cox model, HR 3.8, 95% CI [1.57–9.17], p = 0.003), DSS (Cox
Table 2. (Continued)
Variable MSS MSI high Significance (p)
n (%) n (%)
Disease-specific outcome 0.660
Alive without CRC 93 (68) 23 (62)
Alive with CRC 3 (2) 0 (0)
Dead of CRC 13 (10) 4 (13)
Dead of other cancer 13 (10) 5 (13)
Dead of other causes 10 (7) 5 (13)
Dead cause unspecified 4 (3) 0 (0)
https://doi.org/10.1371/journal.pone.0185436.t002
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Table 3. Ezrin expression in relation to clinicopathological variables (n = 173). CRC = colorectal cancer.
Variable Ezrin low Ezrin high Significance (p)
n (%) n (%)
Gender 0.272
Female 60 (44) 21 (55)
Male 75 (56) 17 (45)
Age 0.130
Under 70 years 56 (41) 10 (26)
Over 70 years 79 (58) 28 (74)
Postoperative stage 0.634
T3N0 113 (84) 30 (79)
T4aN0 13 (10) 4 10)
T4bN0 9 (7) 4 (10)
Tumor side 0.141
Right 65 (48) 24 (63)
Left 70 (52) 14 (37)
Tumor grade 0.119
G1 14 (10) 5 (13)
G2 94 (70) 20 (53)
G3 27 (20) 13 (34)
Histology 0.099
Conventional adenocarcinoma 121 (90) 30 (79)
Mucinous adenocarcinoma 14 (10) 8 (21)
Vascular invasion 0.677
Yes 26 (19) 6 (16)
No 100 (74) 31 (82)
NA 9 (7) 1 (3)
Lymph node count 1.000
12 or more examined 108 (80) 30 (79)
Less than 12 examined 27 (20) 8 (21)
Radicality of surgery 0.568
R0 127 (94) 35 (92)
R1 6 (4) 2 (5)
R2 1 (1) 1 (3)
Preoperative obstruction 0.607
Yes 19 (14) 7 (18)
No 116 (86) 31 (82)
Tumor perforation 0.476
Yes 10 (7) 5 (13)
No 124 (92) 33 (87)
NA* 1 (1) 0 (0)
Adjuvant chemotherapy 1.000
Yes 40 (30) 11 (29)
No 95 (70) 26 (68)
NA* 0 (0) 1 (3)
MSI status 0.001
MSS 117 (87) 19 (50)
MSI 18 (13) 19 (50)
(Continued )
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model, HR 5.44, 95% CI [95% CI 1.3–22.75], p = 0.02), as well as DFS (Cox model, HR 4.87
95% CI [1.38–17.23]; p = 0.014). Moreover, the presence of BRAF mutation was associated to
shortened OS (Cox model, HR 3.29, 95%CI [1.14–9.54], p = 0.028). High ezrin expression
together with MSS were linked to shorter DSS (Cox model, HR 5.68, 95%CI [1.53–21.12],
p = 0.01).
Discussion
Stage II CRC patients possess a treatment challenge, because current diagnostic methods do
not enable their accurate risk stratification. The purpose of this study was to test, whether anal-
ysis of ezrin, a promising prognostic marker, together with microsatellite instability and BRAF
mutation status could be used for prognostication. Indeed, our results show ezrin as an inde-
pendent prognostic marker for disease-specific survival in stage II CRC, and indicate this cor-
relation to be further strengthened by concomitant microsatellite instability testing.
Previous studies by others and us have indicated an association between ezrin expression
and CRC outcome. The earlier studies have been carried out with mixed cohorts, including
various disease stages, which can lead to inaccurate conclusions. However, we are not aware of
any studies that would have specifically focused on ezrin expression in stage II CRC. The cur-
rent results indicate that tumors with high ezrin expression possess adverse biological features
already at a stage, when the cancer has not yet disseminated. Importantly, as demonstrated by
this study, these features are not associated with tumor location, histological grade, vascular
invasion or other outcome-related clinicopathological features. Our results do not clarify the
mechanism, by which ezrin may be linked with oncogenic properties. One explanation is that
ezrin expression provides an advantage for the disseminating cells early on during metastatic
Table 3. (Continued)
Variable Ezrin low Ezrin high Significance (p)
n (%) n (%)
BRAF status 0.001
BRAF WT 121 (91) 25 (66)
BRAF mutated 12 (9) 13 (34)
Disease-specific outcome 0.038
Alive without CRC 93 (69) 23 (61)
Alive with CRC 3 (2) 0 (0)
Dead of CRC 8 (6) 9 (24)
Dead of other cancer 16 (12) 2 (5)
Dead of other causes 11 (8) 4 (11)
Dead cause unspecified 4 (3) 0 (0)
https://doi.org/10.1371/journal.pone.0185436.t003
Table 4. BRAF status in relation to ezrin and MSS/MSI (n = 171).
Variable Ezrin MSS/Ezrin/MSI Significance
(p)
Ezrin low MSS Ezrin low MSI Ezrin high MSS Ezrin high MSI p = 0.0001
n (%) n (%) n (%) n (%)
BRAF mutated 3 (3) 9 (50) 1 (5) 12 (63)
n (%)
BRAF wild type 112 (97) 9 (50) 18 (95) 7 (37)
n (%)
https://doi.org/10.1371/journal.pone.0185436.t004
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seeding. Indeed, some previous studies have indicated a role for ezrin in this process [32,33].
Interestingly, ezrin turned out to be a stronger DSS predictor than any of the clinipathological
factors, apart from tumor perforation.
Ezrin expression is linked to the activity of several oncogenic signaling cascades. Ezrin can
act both as a regulator and/or a down-stream target in several signaling pathways, including
Fig 1. An example of a tumor with MSI-high features and weak ezrin expression. MLH1 (A) and PMS2 (B) are negative in nuclei of cancer cells,
while MSH2 (C) and MSH6 (D) show normal nuclear staining. Tumor cells show weak immunostaining for ezrin (E). This patient had a favorable
prognosis.
https://doi.org/10.1371/journal.pone.0185436.g001
Fig 2. An example of a tumor with MSS features and strong ezrin expression. MLH1 (A), PMS2 (B), MSH2 (C) and MSH6 (D) show normal nuclear
staining in colorectal cancer cells. Tumor cells show strong immunostaining for ezrin (E). This patient had an unfavorable outcome.
https://doi.org/10.1371/journal.pone.0185436.g002
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Src, Akt-PI3K and PKA, and these associations have been suggested to be of importance in
ezrin’s oncogenic properties [34,35,36]. Here, we found that ezrin expression correlated with
BRAF mutation status; high ezrin immunoreactivity being significantly more common in
BRAFV600E than BRAFwild-type tumors. This is a novel finding, there are no previous
reports that would have linked ezrin with BRAF. Even if the specific mechanism of the connec-
tion between these two genes is unknown, the association of both high ezrin expression and
BRAF mutation with the activity of several oncogenic signaling pathways might partly explain
this interesting finding.
In this study, MSI status alone did not correlate with survival, although the superior prog-
nosis of patients with MSI CRC over MSS tumors has been demonstrated earlier in many
Fig 3. Kaplan-Meyer survival analysis of stage II colorectal cancers based on MSI status and ezrin expression. Disease-specific survival (A)
and disease-free survival (B).
https://doi.org/10.1371/journal.pone.0185436.g003
Table 5. Summary of the results in multivariate analysis.
Variable (n) Overall survival Disease-specific survival Disease-free survival
HR 95% CI p value HR 95% CI p value HR 95% CI p value
Stage T3N0 (143) Reference category Reference category Reference category
Stage T4aN0 (17) 1.76 0.64–4.83 0.275 3.40 0.72–15.98 0.121 3.04 0.82–11.33 0.097
Stage T4bN0 (13) 2.86 1.06–7.74 0.038 4.58 0.89–23.62 0.069 8.05 2.31–28.01 0.001
Grade 1 (19) Reference category Reference category Reference category
Grade 2 (114) 0.50 0.20–1.29 0.153 0.93 0.13–6.56 0.946 0.82 0.13–5.21 0.838
Grade 3 (40) 0.53 0.18–1.53 0.241 0.68 0.08–6.12 0.732 1.27 0.18–8.87 0.809
Right colon (89) 1.35 0.69–2.65 0.378 1.27 0.37–4.36 0.702 1.04 0.39–2.83 0.933
Vascular invasion (19) 1.57 0.78–3.18 0.210 3.36 0.98–11.57 0.055 3.62 1.26–10.37 0.017
Perforation (10) 3.80 1.57–9.17 0.003 5.44 1.3–22.75 0.002 4.87 1.38–17.23 0.014
Preop. obstruction (19) 0.71 0.27–1.85 0.479 1.32 0.31–5.65 0.71 1.53 0.45–5.21 0.499
BRAF mutation (12) 3.29 1.14–9.54 0.028 1.41 0.20–9.90 0.728 1.00 0.20–5.07 0.997
Ezrin low MSS (117) Reference category Reference category Reference category
Ezrin low MSI (18) 0.34 0.10–1.15 0.083 0.00 0.00-.000 0.986 0.78 0.09–6.66 0.824
Ezrin high MSS (19) 0.98 0.37–2.64 0.975 5.68 1.53–21.12 0.01 2.76 0.76–1.01 0.124
Ezrin high MSI(19) 0.76 0.26–2.21 0.619 3.19 0.61–16.74 0.17 3.01 0.78–11.66 0.110
https://doi.org/10.1371/journal.pone.0185436.t005
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studies [37,38,13,39,21]. However, the combination of ezrin expression with MSI status strati-
fied the patients to prognostic groups, in which patients with MSS and high ezrin expression
had the shortest DSS and patients with MSI and low ezrin expression had the best DSS (log-
rank test, p = 0.007). This correlation is of interest as high ezrin expression was significantly
more infrequent in MSS tumors than MSI tumors. Why the prognostic role of ezrin is espe-
cially pronounced in MSS tumors awaits further studies.
With this university hospital area based cohort we could confirm earlier findings related to
microsatellite instability and BRAF mutation status. Mucinous histology and poor differentia-
tion grade were associated with MSI, which is in accordance with MSI high phenotype [40]. In
the current study, about a fifth of the tumors were MSI high, and MSI high tumors were signif-
icantly more commonly right-sided, as reported previously for stage II tumors [37,13]. Sided-
ness in itself, however does not justify patient selection for possible adjuvant therapy in stage II
CRC [41].
In the current study, 84% of BRAFmutated tumors were MSI, whereas most BRAFwild
type tumors were MSS. BRAFmutation was also significantly linked to overall survival, the HR
for mortality being 3.29 (95%CI [1.14–9.54], p = 0.028). Similar results have also been reported
in previous studies, showing BRAF mutation to associate with increased mortality due to CRC
[21,42]. There is evidence that MSI phenotype may compensate the poor prognostic effect of
BRAF mutation [43], but this issue remains controversial [44]. BRAF mutation is also reported
to rule out Lynch syndrome [17], which may be of help to the clinicians in counseling the
patients and their families.
At the time-point the patients were treated, MSI-status was not routinely tested among
stage II patients. Altogether, 37% of the patients had received adjuvant chemotherapy, accord-
ing to possible high-risk factors including preoperative obstruction or perforation, vascular
invasion, poor differentiation grade and T4-stage and depending on their overall health, gen-
eral health and patient preference. Patients with MSI tumors are reported not to gain benefit
from fluorouracil-based adjuvant chemotherapy [13,45]. This concerns especially stage II colo-
rectal cancer patients, while there are conflicting results concerning stage III patients [46].
In conclusion, our study found a correlation between ezrin expression and DSS in stage II
CRC, and this correlation was further strengthened by microsatellite instability analysis. Of the
different tumor categories, DSS was longest in patients presenting with MSI / low ezrin tumors
and shortest in MSS / high ezrin tumors. These results imply that ezrin staining can provide
important prognostic information for estimating stage II patients’ individual risk of disease
recurrence and progression.
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